Publication | Open Access

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

Pancreatic CancerMedicinePharmacologyPlatinum-resistant Ovarian CancerCancer TreatmentUnresectable Pancreatic CancerOncologyRadiation OncologyOvarian Cancer